JP2008543340A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543340A5
JP2008543340A5 JP2008518374A JP2008518374A JP2008543340A5 JP 2008543340 A5 JP2008543340 A5 JP 2008543340A5 JP 2008518374 A JP2008518374 A JP 2008518374A JP 2008518374 A JP2008518374 A JP 2008518374A JP 2008543340 A5 JP2008543340 A5 JP 2008543340A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
human
reduced
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008518374A
Other languages
English (en)
Other versions
JP2008543340A (ja
JP4931919B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/024261 external-priority patent/WO2007002261A2/en
Publication of JP2008543340A publication Critical patent/JP2008543340A/ja
Publication of JP2008543340A5 publication Critical patent/JP2008543340A5/ja
Application granted granted Critical
Publication of JP4931919B2 publication Critical patent/JP4931919B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

これらの結果から、IL-βを阻害するAB1、AB5、およびAB7のインビトロ効力が実証される。さらに、ヒト線維芽細胞におけるIL-1β刺激性サイトカイン放出の阻害が、インビボにおけるIL-1媒介活性を阻害する薬剤の能力と相関することが示されている。したがって、これらの結果から、本発明の抗体がインビボにおいてIL-1β阻害効果を有することが示唆される。
アカゲザル、カニクイザル、イヌ、モルモット、およびウサギ由来の新鮮なヘパリン処理全血を、Charles River Labsから入手した。全血をフィコール密度勾配遠心分離により分離し、末梢血単核細胞(PBMC)を単離した。それぞれの種のPBMCについて、2.5x105個細胞/mlを末梢RPMI培地中で、50 ng/mlリポ多糖LPS(大腸菌(E. coli) 055:B5)を添加してまたは添加せずにインキュベートし、刺激の24時間後に上清を回収した。LPSは、PBMCによるIL-1βの産生を促進することが意図される。各上清 2 mlをAB7 2μgと共に3時間インキュベートし、その後プロテインA-Sepharoseビーズスラリー 50μlを添加して、AB7/IL-1β複合体を免疫沈降させた。ヒトIL-1β(Peprotech)をRPMIに添加し、これを免疫沈降/ウェスタンブロット対照とした。プロテインA-Sepharoseビーズを遠心分離し、洗浄した後、全試料をSDS-PAGEゲルに添加し、120 Vで1時間泳動した。Immobilon-P膜に22 Vで一晩転写し、5%脱脂乳でブロッキングした後、2μg/mlのAB7を膜と共に2時間インキュベートした。洗浄段階後に、西洋ワサビペルオキシダーゼ(HRP)結合二次ヤギ抗ヒトIgG抗体を添加し、1段階テトラメチルベンジジン(TMB)溶液で検出した。
図17は、前述の手順で得られたウェスタンブロットを示す。レーン1および2は、それぞれ非還元および還元ヒトIL-1βである。レーン3および4は、それぞれ非還元および還元マウスIL-1βである。レーン5および6は、それぞれ非還元および還元ラットIL-1βである。ブロットの下部に、各レーンにおいて分子量約17 kDaに相当する領域にバンドが認められる。これらのバンドは、IL-1βの存在を示し、ヒトIL-1β、マウスIL-1β、およびラットIL-1βに対するAB7の結合を示すものである。これらの結果から、AB7がげっ歯類IL-1βと交差反応することが示される。
健常ドナーから、新鮮なヘパリン処理末梢血を採取した。全血180μlを96ウェルプレートにプレーティングし、種々の濃度の抗体AB7および100 pM rhIL-1βと共にインキュベートした。Kineret(登録商標)処理試料に関しては、Kineret(登録商標)とrhIL-1βを1:1で混合してから、血液と混合した。試料を37℃、5% CO2にて6時間インキュベートした。次いで、全血細胞を2.5% Triton X-100 50μlで溶解した。清澄化溶解液中のインターロイキン-8(IL-8)の濃度を、製造業者の説明書に従ってELISA(QuantikineヒトIL-8 ELISAキット、R&D Systems)によりアッセイした。AB7およびKineret(登録商標)処理試料中のIL-8濃度を、抗KLH対照で処理した対照試料と比較した。結果を図18に示し、表6に要約する。IC50は、IL-1β刺激によって放出されるIL-8の50%を阻害するのに必要な抗体の濃度である。
AB5を、配列および結合親和性に関してAB対照と比較した。AB5は、配列番号:8に記載される重鎖可変領域および配列番号:9に記載される軽鎖可変領域を含む。AB対照は、配列番号:38に記載される重鎖可変領域および配列番号:39に記載される軽鎖可変領域を含むと考えられている。それらの配列は、米国特許出願公開第2003/0026806の図6Aおよび6Bに記載されている。AB5およびAB対照は、重鎖および軽鎖可変領域において同じ相補性決定領域を有する。それらの重鎖は、配列番号8および38の68位、74位、および86位に位置するフレームワーク領域3内の3アミノ酸残基が異なる。それらの各軽鎖は、配列番号:9および39の72位に位置するフレームワーク領域3内の1アミノ酸残基が異なる。同じCDRを含むそれらの重鎖および軽鎖可変領域の配列における類似性にもかかわらず、AB5とAB対照は、結合親和性が有意にかつ予想外に異なる。上記の実施例1および5において考察したように、AB5は0.3 pM未満の解離定数(KD-low 0.11 pMおよびKD-high 0.56 pM)を有することが認められ、AB対照は3 pMの解離定数(KD-low 1.62 pMおよびKD-high 5.23 pM)を有することが認められた。アミノ酸配列の類似性を考えると、AB5が1けた高い親和性を有することは驚くべきことである。
JP2008518374A 2005-06-21 2006-06-21 ＩＬ−１β結合抗体およびその断片 Active JP4931919B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69283005P 2005-06-21 2005-06-21
US60/692,830 2005-06-21
PCT/US2006/024261 WO2007002261A2 (en) 2005-06-21 2006-06-21 IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011181463A Division JP2011254835A (ja) 2005-06-21 2011-08-23 ＩＬ−１β結合抗体およびその断片

Publications (3)

Publication Number Publication Date
JP2008543340A JP2008543340A (ja) 2008-12-04
JP2008543340A5 true JP2008543340A5 (ja) 2011-10-13
JP4931919B2 JP4931919B2 (ja) 2012-05-16

Family

ID=37595818

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008518374A Active JP4931919B2 (ja) 2005-06-21 2006-06-21 ＩＬ−１β結合抗体およびその断片
JP2011181463A Pending JP2011254835A (ja) 2005-06-21 2011-08-23 ＩＬ−１β結合抗体およびその断片

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011181463A Pending JP2011254835A (ja) 2005-06-21 2011-08-23 ＩＬ−１β結合抗体およびその断片

Country Status (24)

Country Link
US (11) US7531166B2 (ja)
EP (5) EP2163562B1 (ja)
JP (2) JP4931919B2 (ja)
KR (3) KR101502920B1 (ja)
CN (2) CN102775493B (ja)
AT (1) ATE446972T1 (ja)
AU (1) AU2006262179B2 (ja)
BR (1) BRPI0612273C1 (ja)
CA (2) CA2873914A1 (ja)
CY (3) CY1109715T1 (ja)
DE (1) DE602006010072D1 (ja)
DK (4) DK2314623T3 (ja)
ES (5) ES2569917T3 (ja)
HK (3) HK1140781A1 (ja)
HU (1) HUE029021T2 (ja)
IL (2) IL188094A (ja)
MX (2) MX348154B (ja)
NZ (1) NZ565138A (ja)
PL (4) PL2163562T3 (ja)
PT (3) PT2163562E (ja)
RU (1) RU2518295C2 (ja)
SI (4) SI2314623T1 (ja)
WO (1) WO2007002261A2 (ja)
ZA (1) ZA200800555B (ja)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2163562T3 (pl) 2005-06-21 2014-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
EP3332807B1 (en) 2005-10-26 2023-02-22 Novartis AG Use of anti il-1beta antibodies
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
PT2068889T (pt) * 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
CA2839162A1 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Methods for the treatment of il-1-.beta. related diseases
CN103405768A (zh) * 2006-12-20 2013-11-27 爱克索马技术有限公司 用于治疗IL-1β相关疾病的方法
CA3080328C (en) 2007-05-29 2022-06-21 Novartis Ag New indications for anti-il-1-beta therapy
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
EP2293816B1 (en) * 2008-06-06 2012-11-07 XOMA Technology Ltd. Methods for the treatment of rheumatoid arthritis
EP2341936A4 (en) * 2008-09-05 2012-07-25 Xoma Technology Ltd METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
EP4104821A1 (en) * 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
RU2011135768A (ru) * 2009-01-29 2013-03-10 Эбботт Лэборетриз Белки, связывающие il-1
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US20130122008A1 (en) * 2009-05-06 2013-05-16 Novartis Ag Anti-IL 1- ß Antibody Combination Therapy
CA2763161A1 (en) * 2009-05-29 2010-12-02 Xoma Technology Ltd. Cardiovascular related uses of il-1.beta. antibodies and binding fragments thereof
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
PL3438126T3 (pl) * 2009-09-03 2021-03-08 Ablynx N.V. Stabilne formulacje polipeptydów i ich zastosowanie
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
JP2013507929A (ja) * 2009-10-15 2013-03-07 アボット・ラボラトリーズ Ｉｌ−１結合蛋白質
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
SG2014014724A (en) * 2010-05-07 2014-07-30 Xoma Technology Ltd METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
NZ607510A (en) * 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
TW201527322A (zh) * 2011-02-08 2015-07-16 Abbvie Inc 骨關節炎及疼痛之治療
AU2012242666A1 (en) 2011-04-15 2013-11-28 Merck Patent Gmbh Anti- IL-1R1 inhibitors for use in cancer
JP6184942B2 (ja) 2011-06-03 2017-08-23 メゾブラスト，インコーポレーテッド 神経疾患を治療するまたは予防する方法
WO2013007763A1 (en) 2011-07-12 2013-01-17 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
TWI461192B (zh) * 2011-07-20 2014-11-21 Twi Biotechnology Inc 降低血脂異常病患之糖化血色素的醫藥組成物
DE102011083595A1 (de) * 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
BR112014007253A2 (pt) 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
CN104144946A (zh) * 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
EP2623604B8 (en) * 2012-02-02 2015-04-22 Baylor College of Medicine Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis
RS60583B1 (sr) * 2012-02-13 2020-08-31 Agency Science Tech & Res Ljudska monoklonalna antitela koja vrše neutralizaciju il-ss
WO2014033252A1 (en) * 2012-08-31 2014-03-06 arGEN-X BV Method for producing antibody molecules having inter-species, intra-target cross-reactivity
KR102345999B1 (ko) * 2012-11-05 2021-12-30 델레넥스 쎄라퓨틱스 아게 Il-1 베타 결합성분
EP2931750B8 (en) * 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
NZ710900A (en) * 2013-02-15 2019-09-27 R Pharm International Llc Il-1β inhibitor composition and use thereof
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
CN105980556B (zh) * 2013-12-26 2020-10-09 田边三菱制药株式会社 人抗il－33中和单克隆抗体
WO2016008851A1 (en) * 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
TN2017000482A1 (en) 2015-05-18 2019-04-12 Bayer Pharma AG Selective progesterone receptor modulator (sprm) regimen.
JP6501650B2 (ja) * 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗ｉｌ−３３中和モノクローナル抗体
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CN108218978B (zh) * 2016-12-13 2020-05-12 沈阳何氏眼产业集团有限公司 一种重组白细胞介素18及其制备方法与应用
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
EP3677281A4 (en) 2017-08-31 2021-05-12 Mitsubishi Tanabe Pharma Corporation THERAPEUTIC AGENT CONTAINING AN IL-33 ANTAGONIST TO TREAT ENDOMETRIOSIS
JP2020533353A (ja) 2017-09-13 2020-11-19 ノバルティス アーゲー アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
WO2021116789A1 (en) 2019-12-09 2021-06-17 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
US20230068783A1 (en) * 2020-01-21 2023-03-02 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
WO2022167916A1 (en) 2021-02-03 2022-08-11 Novartis Ag Use of il-1b binding antibodies for treating neuroinflammatory disorders
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493543A (en) * 1893-03-14 Lap-ring
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5077219A (en) * 1984-05-18 1991-12-31 New England Medical Center Hospitals Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
DE3588241T2 (de) 1984-05-18 2002-12-05 New England Medical Center Inc Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5122459A (en) * 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5474899A (en) 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5077218A (en) * 1988-05-05 1991-12-31 Oregon Lions Sight And Hearing Foundation Inc. Eye transport apparatus
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE68925935T2 (de) * 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0460052T3 (da) * 1989-02-27 1999-03-08 New England Medical Center Inc Inhibitorer af IL-1's biologiske aktivitet
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DE69233782D1 (de) * 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2507749C (en) * 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
WO1994000470A1 (en) * 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
ATE195652T1 (de) 1992-12-02 2000-09-15 Alkermes Inc Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
ATE197398T1 (de) 1994-09-09 2000-11-11 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
WO1996012792A1 (en) * 1994-10-20 1996-05-02 Merck & Co., Inc. INTERLEUKIN-1β DEFICIENT TRANSGENIC ANIMALS
RU2147442C1 (ru) * 1994-10-21 2000-04-20 Кисимото Тадамицу Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6
AU695207B2 (en) 1995-03-28 1998-08-06 Fidia Farmaceutici S.P.A. Nanospheres comprising a biocompatible polysaccharide
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5817476A (en) 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
WO1996040072A2 (en) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6057103A (en) 1995-07-18 2000-05-02 Diversa Corporation Screening for novel bioactivities
US6168919B1 (en) 1996-07-17 2001-01-02 Diversa Corporation Screening methods for enzymes and enzyme kits
US6455254B1 (en) 1995-07-18 2002-09-24 Diversa Corporation Sequence based screening
US6030779A (en) 1995-07-18 2000-02-29 Diversa Corporation Screening for novel bioactivities
US5958672A (en) 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US6004788A (en) 1995-07-18 1999-12-21 Diversa Corporation Enzyme kits and libraries
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US5939250A (en) 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6368798B1 (en) 1995-12-07 2002-04-09 Diversa Corporation Screening for novel bioactivities
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6489145B1 (en) 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling
US6344328B1 (en) 1995-12-07 2002-02-05 Diversa Corporation Method for screening for enzyme activity
US20030215798A1 (en) 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
JP4018154B2 (ja) * 1996-10-31 2007-12-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Ｉｃｅ阻害ペプチド
CA2287254A1 (en) * 1997-04-21 1998-10-29 Schering Corporation Mammalian cytokines; related reagents and methods
US6337186B1 (en) 1998-06-17 2002-01-08 Maxygen, Inc. Method for producing polynucleotides with desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
WO2000052155A2 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP2241328A1 (en) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20030166069A1 (en) 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US6864047B2 (en) * 2001-03-29 2005-03-08 Mayo Foundation For Medical Education And Research IL1-β: a new target for myeloma therapy
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
WO2003010282A2 (en) * 2001-07-26 2003-02-06 Eli Lilly And Company Interleukin-1 beta antibodies
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
CA2842429A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US6673552B2 (en) 2002-01-14 2004-01-06 Diversa Corporation Methods for purifying annealed double-stranded oligonucleotides lacking base pair mismatches or nucleotide gaps
EP1481010A2 (en) 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
US7572770B2 (en) 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
KR101101261B1 (ko) 2002-07-19 2012-01-04 인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링 생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
WO2004039834A2 (en) 2002-11-01 2004-05-13 Alk-Abelló A/S Recombinant protein variants
EP1590369B1 (en) * 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040266993A1 (en) 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
WO2005019259A2 (en) 2003-08-25 2005-03-03 Compugen Ltd. Variants of interleukin-1 receptor antagonist: compositions and uses thereof
US20050152850A1 (en) * 2004-01-09 2005-07-14 Engebretson Steven P. Methods and compositions for facilitating metabolic control
US7732478B2 (en) * 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control
WO2005084696A1 (en) 2004-03-08 2005-09-15 Universita'degli Studi Di Milano Methods and agents for controlling intestinal inflammation and mucosal immunity using agents interacting with tir8/sigirr
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PL2163562T3 (pl) 2005-06-21 2014-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
FR2895611B1 (fr) 2005-12-23 2008-02-22 Thales Sa Architecture et procede pour controler le transfert d'informations entre utilisateurs
US8479265B2 (en) * 2008-07-02 2013-07-02 Oracle International Corporation Usage based authorization

Similar Documents

Publication Publication Date Title
JP2008543340A5 (ja)
Imai et al. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis
EP0267611B1 (en) Antibody against interleukin-1
RU2728964C2 (ru) Способ и композиция для лечения рака, уничтожения метастатических раковых клеток и профилактики метастазов рака, используя антитела к конечным продуктам повышенного гликирования ( AGE)
Fischer et al. Combined inhibition of tumor necrosis factor α and interleukin‐17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody
DK1954718T3 (en) Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
KR0150060B1 (ko) 사람 인터루킨-5에 대한 인간화 모노클로날 항체의 고안, 클로닝 및 발현
EP1536012A1 (en) Human antihuman interleukin-6 antibody and fragment of the antibody
WO2005026209A2 (en) Monoclonal antibodies against hmgb1
KR20110031989A (ko) 진단용 항체 검사법
Oortwijn et al. A pathogenic role for secretory IgA in IgA nephropathy
EP2222704A1 (en) 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
EP2231707A1 (en) Anti mif antibodies
US20210061895A1 (en) Antibody binding a linear epitope of human p53 and diagnostic applications thereof
CA2690888A1 (en) Cancer therapeutic composition comprising antibody against peptide encoded by exon-17 site of periostin
US6214568B1 (en) Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof
JPWO2004029242A1 (ja) フォンビルブランド因子特異的切断酵素に対する抗体及びそれを用いたアッセイ系
JP6976566B2 (ja) イヌアトピー性皮膚炎の治療及び診断のために用いる抗イヌｔａｒｃ抗体
JP7256266B2 (ja) ヒトＩＬ－１βに結合する抗体、その調製方法及び用途
JP6815632B2 (ja) 抗硫酸フェニル誘導体抗体
WO2011074965A1 (en) Methods and means for counteracting an activity of an fc domain
Janda et al. Generation of equine TSLP-specific antibodies and their use for detection of TSLP produced by equine keratinocytes and leukocytes
Gilbert et al. Production of a human monoclonal anti-epithelial cell surface antibody derived from a patient with pemphigus vulgaris
JP3623985B2 (ja) 抗ｌｄ７８ポリペプチドモノクローン抗体
CA2342199C (en) Monoclonal antibodies against s100